

Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells

Veronica Tisato,¹ Alessia Norcio,¹¹ Claudio Celeghini,¹¹¹ Daniela Milani,¹ Arianna Gonelli,¹ Paola Secchiero¹

¹ University of Ferrara, Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, Ferrara, Italy. ¹¹ Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. ¹¹¹ University of Trieste, Department of Life Sciences, Trieste, Italy.

OBJECTIVE: It has been shown that SOCS-1 plays an important role in the proper control of cytokine/growth factor responses and acts as a tumor suppressor in acute myeloid leukemias. Therefore, the objective of the present study was to evaluate the *in vitro* effect of treatment with Nutlin-3, a small molecule inhibitor of the MDM2/p53 interaction, on the expression of the suppressor of cytokine signaling 1 in primary acute myeloid leukemia cells and in myeloid cell lines with differential p53 status.

METHOD: The expression of the suppressor of cytokine signaling 1 was quantitatively analyzed by real-time PCR in myeloid p53^{wild-type} (OCI and MOLM) and p53^{null} HL-60, leukemic cell lines, in patient-derived acute myeloid leukemia blasts, and in primary normal cell types, such as macrophages, endothelial cells, and bone marrow mesenchymal stem cells. The p53-dependence of the suppressor of cytokine signaling 1 upregulation that is induced by Nutlin-3 was analyzed in experiments performed using siRNA for p53, while the functional upregulation of the suppressor of cytokine signaling 1 was analyzed by assessing the levels of phosphorylated STAT-3.

RESULTS: Nutlin-3 significantly upregulated the transcription of the suppressor of cytokine signaling 1 in p53^{wild-type} OCI and MOLM but not in p53^{deleted} p53^{null} HL60, myeloid leukemic cell lines, as well as in primary acute myeloid leukemia blasts. Conversely, and somewhat unexpectedly, Nutlin-3 did not modulate the suppressor of cytokine signaling 1 expression in primary normal macrophages, endothelial cells, and bone marrow mesenchymal stem cells. The p53-dependent upregulation of the suppressor of cytokine signaling 1 by Nutlin-3 was associated with the downregulation of phosphorylated STAT-3, a major molecular target of the suppressor of cytokine signaling 1.

CONCLUSION: Overall, our data suggest a potential role for the suppressor of cytokine signaling 1 as a therapeutic target of Nutlin-3 in p53 wild-type acute myeloid leukemias.

KEYWORDS: Nutlin-3; SOCS-1; AML.

Tisato V, Norcio A, Celeghini C, Milani D, Gonelli A, Secchiero P. Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells. *Clinics*. 2014;69(1):68-74.

Received for publication on May 13, 2013; First review completed on June 5, 2013; Accepted for publication on July 16, 2013

E-mail: veronica.tisato@unife.it

Tel.: 39 0532-455572

INTRODUCTION

The selective small molecule inhibitor Nutlin-3 binds MDM2 in the p53 binding pocket with high selectivity and can release p53 from negative control, leading to an effective stabilization of p53 and activation of the p53 pathway (1). A number of studies have demonstrated that Nutlin-3 induces *ex vivo* cytotoxic cell death of p53^{wild-type} acute myeloid leukemias (AMLs) (2–7), and Nutlin-3 was recently shown to upregulate the suppressor of cytokine signaling 1 (SOCS-1) in primary B leukemic cells through the *mirR-155* pathway (8,9). Since the cloning of *SOCS-1*, it has become evident that the

SOCS proteins are important for the proper control of cytokine and growth factor responses, and the absence of SOCS proteins leads to excessive cytokine signaling (10). In addition, SOCS-1 also acts as a tumor suppressor, as documented by the fact that *SOCS-1* silencing by DNA hypermethylation at the gene promoter region has been found in both solid tumors, such as hepatocarcinomas (11), and AMLs (12–17).

Based on these findings, in the present study, we evaluated the effect of Nutlin-3 treatment on SOCS-1 expression in primary AML cells, as well as in myeloid cell lines with differential p53 status. Additionally, the effect of Nutlin-3 exposure on SOCS-1 expression was evaluated in primary normal cells characteristic of the bone marrow microenvironment, such as primary macrophages, endothelial cells, and multipotent stromal cells (MSCs).

MATERIALS AND METHODS

Cell culture

The myeloid p53^{wild-type} (OCI and MOLM) and p53^{null} (HL-60) leukemic cell lines were purchased from the ATCC

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

DOI: 10.6061/clinics/2014(01)10



(American Type Culture Collection, Manassas, VA). MOLM and HL-60 leukemic cell lines were cultured in RPMI-1640 containing 10% FBS (both from Gibco BRL, Grand Island, NY), while OCI cells were cultured in alpha-MEM (LONZA, Basel, Switzerland) containing 10% FBS, as previously described (18).

Primary peripheral blood samples were collected in heparin-coated tubes from five AML patients and six healthy blood donors after informed consent was obtained in accordance with the Declaration of Helsinki and in agreement with institutional guidelines. Peripheral blood mononuclear cells (PBMC) from AML patients and healthy donors were isolated by gradient centrifugation with lymphocyte cell separation medium (Cedarlane Laboratories, Hornby, ON). The percentage of blasts among leukemic PBMC ranged from 60–85% for all patients, as assessed by light microscopy and verified by standard flow cytometry analysis. AML patient cells were seeded at a density of 1×10^6 cells/ml in RPMI containing 10% FBS (both from Gibco BRL). To obtain primary normal adherent macrophages, blood donor PBMCs were seeded at a density of 5×10^6 cells/ml, and non-adherent cells were removed after 18 hours. Adherent cells were cultivated in fresh RPMI medium containing 10% FBS, as previously described (19).

Human umbilical vein endothelial cells (HUVECs) were purchased from BioWhittaker (Walkersville, MD) and grown on 0.2% gelatin-coated tissue culture plates in M199 endothelial growth medium supplemented with 20% FBS, heparin, and 50 mg/ml ECGF (all from BioWhittaker), as previously described (20). In all experiments, cells were used between the 3rd and 5th passage *in vitro*. Bone marrow-derived MSCs were purchased from LONZA and grown in MSC Growth Medium (MSC-GM, LONZA), as previously described (21,22).

Culture treatments and evaluation of cell cytotoxicity

Cells were treated by adding Nutlin-3 (10 μ M; obtained from Cayman Chemical, Ann Arbor, MI) to the culture medium. After treatment, cell viability was monitored up to 48 hours by Trypan blue dye exclusion, as previously described (23). In parallel, the degree of apoptosis was quantified by Annexin V-FITC/propidium iodide (PI) staining (Immunotech, Marseille, France) followed by flow cytometry analysis, as previously described (24,25). To analyze the cell cycle profile, cells were incubated with 50 μ M 5-bromodeoxyuridine (BrdU; Sigma Aldrich) at 37°C for 1 hour, the anti-BrdU antibody (BD Biosciences Pharmingen, Franklin Lakes, NJ) was bound to BrdU, and the complex was detected by an FITC-conjugated secondary antibody (Beckman-Coulter, Marseille, France) (26,27). After additional staining with 50 μ g/ml PI (Sigma-Aldrich), the cell samples were analyzed by flow cytometry.

RNA analysis

Aliquots of untreated and Nutlin-3-treated cells were harvested for RNA extraction 24–48 hours post-treatment. Total RNA was extracted using the Qiagen RNeasy Plus mini kit (Qiagen, Hilden, Germany) according to the supplier's instructions. The integrity of the total RNA preparation was assessed using an Agilent 2100 Bioanalyzer. RNA was transcribed into cDNA using the GEArray AmpoLabeling-LPR Kit (Superarray Bioscience Corporation, Frederick, MD). Investigations of *SOCS-1* and *miR-155* gene expression were both carried out in RNA

samples with the real-time thermal analyzer Rotor-Gene™ 6000 (Corbett, Cambridge, UK) using SYBR Green-based technology and the RT-PCR primer set for human *SOCS-1* cDNA or *miR-155* (SABioscience, Frederick, MD). Gene expression of the target sequences was normalized with respect to the expression of endogenous controls. Each sample was tested in triplicate.

Western blot analyses

Cells were lysed in ice-cold RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 0.25% sodium desoxycholate) supplemented with protease inhibitors (Complete, Roche; Germany) on ice for 1 hour (28). Before gel migration, samples were added to loading buffer (250 mM Tris pH 6.8, 2% SDS, 40% glycerol, 20% beta-mercaptoethanol) and boiled for 2 minutes. Equal amounts of protein for each sample were migrated in acrylamide gels and blotted onto nitrocellulose filters, as previously described (29), before incubation with the following monoclonal antibodies: anti-p53, anti-*SOCS-1*, anti-STAT-3, and anti-phospho-STAT-3 (all from Santa Cruz Biotechnology, Santa Cruz, CA), as well as anti-tubulin (Sigma-Aldrich). After incubation with peroxidase-conjugated anti-mouse IgG, specific reactions were revealed with the ECL detection kit (Amersham Pharmacia Biotech).

Multiplex immunoassay

The MILLIPLEX MAP Human Multi-Pathway 9-plex Magnetic Bead Signaling kit phosphoprotein (Merck Millipore, Billerica, MA, USA) was used to detect changes in phosphorylated ERK/MAP kinase 1/2, Akt, STAT-3, JNK, p70 S6 kinase, NF- κ B, STAT-5A/B, CREB, and p38 in cell lysates using the Luminex system, according to the manufacturer's instructions. Briefly, cells were seeded at a density of 1×10^6 /ml and treated with Nutlin-3 (10 μ M). At different time points, cells were harvested in MILLIPLEX MAP lysis buffer (Merck Millipore) in the presence of the Protease Inhibitor Cocktail Set III (Calbiochem, San Diego, CA). Each lysate was diluted in the MILLIPLEX MAP Assay Buffer 2 (Merck Millipore), incubated at 4°C overnight, and analyzed according to the assay protocol. Median Fluorescence Intensity (MFI) was measured with the Luminex System and normalized for μ g of protein.

Transfection experiments

OCI cells (1.25×10^6) were resuspended in 0.1 ml of Nucleofector™ solution V from the human Nucleofector kit V (Amaxa, Cologne, Germany). Two μ g of plasmid DNA (GFP-construct) or 1 μ g of siRNA was mixed with the 0.1 ml of cell suspension, transferred into a 2.0-mm electroporation cuvette, and nucleofected using an Amaxa Nucleofector II apparatus, following the manufacturer's guidelines and as previously described (30). After transfection, cells were immediately transferred into complete medium and cultured in six-well plates at 37°C. Transfection efficiency was estimated in each experiment by scoring the number of GFP-positive cells by flow cytometry analysis. siRNAs were designed and manufactured by Ambion Inc. (Austin, TX) according to the current guidelines for effective gene knock-down by this method and were validated in preliminary experiments. Negative control siRNA, comprised of a 19-bp scrambled sequence with 3' dT overhangs (Ambion's *Silencer* negative control siRNA), was used to demonstrate that transfection did not induce non-specific effects on gene



expression. In *miR-155* functional studies, cells were transfected with the *hsa-miR-155* anti-miR oligo to inhibit the activity of endogenous *miR-155*. In parallel, cells were transfected with the FAM-labeled miR negative control oligo as a non-targeting negative control and to monitor transfection efficiency. All oligos were obtained from Ambion.

Statistical analysis

Descriptive statistical analyses were conducted. For each set of experiments, values are reported as the mean ± SD. Data were analyzed with Student's *t* test, and statistical significance was defined as *p* < 0.05.

RESULTS

Upregulation of SOCS-1 expression in p53^{wild-type} AML cells by Nutlin-3

In the first group of experiments, we investigated whether Nutlin-3 affected the expression of *SOCS-1* mRNA in AML cells. For this purpose, we assessed both patient (n=5) AML blasts and myeloid cell lines, characterized by either p53^{wild-type} (OCI and MOLM) or p53^{null} (HL-60) status. As reported in Table 1, Nutlin-3 induced significant cytotoxicity in all patient AML blast cultures and p53^{wild-type} myeloid cell lines but not in p53^{null} HL-60 cells, which is consistent with the ability of Nutlin-3 to induce apoptosis and cell cycle arrest (2,4). Moreover, as shown in Figure 1A, treatment with Nutlin-3 induced a significant (*p* < 0.05) increase in *SOCS-1* mRNA levels in all primary AML blasts and in p53^{wild-type} OCI and MOLM cells but not in p53^{null} HL-60 cells. In an attempt to also evaluate *SOCS-1* protein, we analyzed cell lysates by the Western blot assay. However, under our experimental conditions, the commercially available antibodies did not allow for clear and reproducible protein detection (data not shown). The data shown in Figure 1A suggest but do not prove that the Nutlin-3-mediated upregulation of *SOCS-1* in leukemic cells requires a functional p53 pathway. Therefore, to ascertain the role of p53 in Nutlin-3-induced upregulation of *SOCS-1*, we used pre-determined optimal experimental conditions to transfect siRNA against *p53* in OCI cells to specifically knock down *p53* gene expression. As shown in Figure 1B, *p53* knock down counteracted the ability of Nutlin-3 to increase the level of p53 protein in OCI cells and significantly (*p* < 0.05) counteracted the ability of Nutlin-3 to upregulate *SOCS-1* expression. These data demonstrate that the ability of Nutlin-3 to transcriptionally

Table 1 - Effect of Nutlin-3 treatment on myeloid leukemic cell viability.

| Myeloid leukemic cells | Cell viability of Nutlin-3 treated cultures (% of untreated cultures) ^a |
|------------------------|--|
| OCI | 30 ± 7 |
| MOLM | 6 ± 3 |
| HL60 | 88 ± 10 |
| Pt. 1 | 23 ± 6 |
| Pt. 2 | 29 ± 8 |
| Pt. 3 | 36 ± 9 |
| Pt. 4 | 22 ± 5 |
| Pt. 5 | 32 ± 6 |

^aLeukemic cells were exposed to Nutlin-3 (10 μM) and cell viability was analysed at 48 hours of treatment. Data are reported as means ± SD of at least three independent experiments.

upregulate *SOCS-1* expression in myeloid leukemic cells is dependent on p53.

The recent data demonstrating that Nutlin-3 downregulates *miR-155* in primary B-CLL (8), along with a key role for *miR-155* in regulating *SOCS-1* expression (9,31,32), together supported the investigation of *miR-155* knock down on *SOCS-1* expression in response to Nutlin-3 in AML cell models. For this purpose, OCI cells were transfected either with the *hsa-miR-155* anti-miR oligo to inhibit the activity of endogenous *miR-155* or with the miR negative control oligo before exposure to Nutlin-3. Treatment with Nutlin-3 increased the levels of *SOCS-1* mRNA in control (miR negative control oligo) transfected cells, and this effect was enhanced in cells transfected with *anti-miR-155* (Figure 1C). Although these experiments did not address a potential direct link between Nutlin-3 and *miR-155*, which also acts as oncomiR in AML (33,34), they confirm an important role for *miR-155* in *SOCS-1* transcriptional modulation and show that *anti-miR-155* enhances the ability of Nutlin-3 to upregulate *SOCS-1* mRNA expression in AML cells.

Because *SOCS-1* is known to affect the intracellular signaling pathways downstream of several cytokines and one of its major targets is represented by the inhibition of the JAK/STAT-3 pathway (10,11), we analyzed the functionality of Nutlin-3-mediated induction of *SOCS-1* by assessing the levels of phosphorylated STAT-3. For this purpose, leukemic cells were exposed to Nutlin-3 (10 μM), and at different time points, the phosphorylation pattern of the main intracellular pathways was evaluated by a multiplex assay. Among the activated pathways (Figure 2), phosphorylation levels of both ERK1/2 and p38, although characterized by different baseline kinetics, were unaffected by Nutlin-3 exposure (Figure 2A). Of interest, STAT-3 phosphorylation, characterized by a progressive increase over time in untreated cultures, was significantly inhibited after 24 hours of Nutlin-3 treatment, as further confirmed by Western blot analysis (Figure 2B). Overall, these results are consistent with those of a previous study showing that ERK1/2 is not affected by *SOCS-1* (35), and they validate the ability of *SOCS-1* to downregulate the JAK/STAT-3 pathway upon Nutlin-3 treatment of leukemic cells.

Lack of *SOCS-1* modulation by Nutlin-3 in primary normal macrophages, endothelial cells, and MSC


Because *SOCS-1* plays a role in different cell types (10), we analyzed whether Nutlin-3 was able to also modulate *SOCS-1* in primary normal cells, such as normal macrophages, endothelial cells, and bone marrow MSCs, which represent the relevant cytotypes present in the bone marrow micro-environment. As shown in Figure 3, Nutlin-3 did not significantly modulate *SOCS-1* expression in any of the primary cell types investigated, suggesting that the ability of Nutlin-3 to upregulate *SOCS-1* was confined to p53^{wild-type} malignant AML cells (Figure 3).

DISCUSSION


Previous findings indicated that *SOCS-1* may function as a tumor suppressor and that it is frequently found to be silenced in hematopoietic malignancies. In this context, we have demonstrated that a novel non-genotoxic activator of the p53 pathway, Nutlin-3, is able to significantly upregulate *SOCS-1* expression in primary AML blasts as well as in p53^{wild-type} myeloid OCI and MOLM cell lines, but not in



A



B



C





Figure 1 - Transcriptional upregulation of *SOCS-1* by Nutlin-3 in AML cells. In **A**, AML cell lines and primary AML patient (Pt.) cells were exposed to Nutlin-3 (10 μ M). Levels of *SOCS-1* mRNA were analyzed by quantitative RT-PCR. The results are expressed as the fold of increase in *SOCS-1* modulation by Nutlin-3 after 24 hours of treatment with respect to the control untreated cultures (set to 1) (hatched line). Data are reported as the mean \pm SD of the results from at least three experiments, each performed in triplicate. In **B**, OCI cells were transfected with control scrambled (scr.) siRNA or *p53* siRNA before treatment with Nutlin-3. *p53* protein levels were analyzed by Western blot, and tubulin staining is shown as the loading control. Representative examples of Western blot results, from three independent experiments are shown. In parallel, levels of *SOCS-1* mRNA were expressed as the fold increase with respect to the scrambled control transfected cultures. In **C**, OCI cells transfected with either *hsa-miR-155* anti-miR oligo or miR negative control oligo were exposed to Nutlin-3 and *SOCS-1* mRNA was expressed as the fold increase in modulation. Asterisks, $p < 0.05$ with respect to the untreated cultures or to the scrambled control transfected cultures.

p53^{null} HL-60 cells. In addition, we have demonstrated that the upregulation of *SOCS-1* was functional because this upregulation resulted in a significant downregulation of

STAT-3 phosphorylation levels. It is important to note that the activation of STAT-3 has been frequently reported in both primary human acute leukemia and leukemic cell lines (36),



A



B




Figure 2 - Phosphorylation patterns of Nutlin-3-treated AML cells. Leukemic cells were exposed to Nutlin-3 (10 μ M), and phosphoprotein levels were analyzed in cell lysates by the Multiplex assay at the indicated time points. Phosphoprotein levels are expressed as the median fluorescence intensity (MFI). Data are reported as the mean \pm SD. In **A**, phosphorylation levels of ERK1/2 and p38 in untreated and Nutlin-3-treated cultures are shown. In **B**, phosphorylation levels of STAT-3 in untreated and Nutlin-3-treated cultures, analyzed with the Multiplex assay and validated by Western blot analysis, are shown. Asterisks, $p < 0.05$ with respect to the untreated cultures.

as well as that STAT-3 represents a major molecular target of SOCS-1 (10,11). However, no modulation of SOCS-1 was observed in primary normal macrophages, endothelial cells, or bone marrow MSC, suggesting that Nutlin-3 selectively upregulated SOCS-1 in malignant cells but not in normal cells of the bone marrow microenvironment. To date, we do not have an explanation for this differential activity of Nutlin-3 in myeloid leukemia cells and primary normal cells. We cannot exclude the possibility that Nutlin-3-mediated upregulation of SOCS-1 is also dependent on its ability to arrest cell cycle progression in highly cycling malignant cells, as some experimental observations (generated by blocking the cell cycle with different pharmacological agents) potentially support this hypothesis. However, these data are still too preliminary to draw any major conclusions. Additionally, a cycle-related effect of Nutlin-3 in upregulating SOCS-1 was also suggested by the more robust SOCS-1 induction

in leukemic cell lines (3- to 8-fold) compared with primary AML (2- to 4-fold), a result also previously reported for primary B-CLL cells (2- to 4-fold; 9). Thus, further investigation is clearly needed to elucidate the molecular mechanisms underlining the differential behavior of Nutlin-3 with respect to SOCS-1 induction in normal cells compared with malignant cells.

A second interesting finding of our study was the identification that the Nutlin-3-mediated upregulation of SOCS-1 was potentiated by a concomitant downregulation of *miR-155*, which is known to act as an oncomiR in AML (33,34). Thus, SOCS-1 represents a potential common target between Nutlin-3 and *antago-miR-155*.

In conclusion, our data demonstrate that Nutlin-3, a small molecule with great therapeutic potential in hematological malignancies (37,38), upregulates the SOCS-1 pathway in leukemic cells but apparently not in normal quiescent cells.




Figure 3 - Lack of transcriptional modulation of SOCS-1 by Nutlin-3 in normal cells. Normal adherent PBMC, endothelial cells, and MSC were exposed to Nutlin-3 (10 μ M). Levels of SOCS-1 mRNA were analyzed by quantitative RT-PCR. The results are expressed as the fold increase in SOCS-1 modulation by Nutlin-3 after 24 hours of treatment with respect to the control untreated cultures (set to 1) (hatched line). Data are reported as the mean \pm SD of the results from at least three experiments, each performed in triplicate.

Due to the role of SOCS-1 as an oncosuppressor, therapeutic combinations based on Nutlin-3 warrant further investigations with regard to the treatment of AML.

ACKNOWLEDGMENTS

This work was supported by the Regione Friuli Venezia Giulia - AITT Project.

AUTHOR CONTRIBUTIONS

Tisato V, Norcio A, Celeghini C, Gonelli A, and Milani D performed the experiments. Tisato V and Norcio A analyzed the data. Secchiero P designed the study and wrote the manuscript. All authors have read and approved the manuscript.

REFERENCES

- Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. *Curr Pharm Des.* 2008;14(21):2100-10, <http://dx.doi.org/10.2174/138161208785294663>.
- Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. *Curr Pharm Des.* 2011;17(6):569-77, <http://dx.doi.org/10.2174/138161211795222586>.
- Secchiero P, Zerbinati C, Melloni E, Milani D, Campioni D, Fadda R, et al. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. *Neoplasia.* 2007;9(10):853-61, <http://dx.doi.org/10.1593/neo.07523>.
- Secchiero P, Melloni E, di Iasio MG, Tiribelli M, Rimondi E, Corallini F, et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. *Blood.* 2009;113(18):4300-8, <http://dx.doi.org/10.1182/blood-2008-11-187708>.
- Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinjima N, et al. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 α -mediated down-regulation of CXCL12. *Blood.* 2011;118(16):4431-9, <http://dx.doi.org/10.1182/blood-2011-02-334136>.
- Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME, et al. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. *Clin Cancer Res.* 2011;17(9):2712-24, <http://dx.doi.org/10.1158/1078-0432.CCR-10-3244>.
- McCormack E, Haaland I, Venàs G, Forthun RB, Huseby S, Gausdal G, et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. *Leukemia.* 2012;26(5):910-7, <http://dx.doi.org/10.1038/leu.2011.315>.
- di Iasio MG, Addobbati R, Radillo O, Voltan R. Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. *Invest New Drugs.* 2012;30(4):1761-5, <http://dx.doi.org/10.1007/s10637-011-9695-4>.
- di Iasio MG, Norcio A, Melloni E, Zauli G. SOCS1 is significantly up-regulated in Nutlin-3-treated p53(wild-type) B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. *Invest New Drugs.* 2012;30(6):2403-6, <http://dx.doi.org/10.1007/s10637-011-9786-2>.
- Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. *Nat Rev Immunol.* 2002;2(6):410-6.
- Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. *Nat Genet.* 2001;28(1):29-35.
- Chen CY, Tsay W, Tang JL, Shen HL, Lin SW, Huang SY, et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. *Genes Chromosomes Cancer.* 2003;37(3):300-5, <http://dx.doi.org/10.1002/gcc.10222>.
- Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H, et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. *Br J Haematol.* 2004;126(5):726-35, <http://dx.doi.org/10.1111/j.1365-2141.2004.05107.x>.
- Ekmekci CG, Gutiérrez MI, Siraj AK, Ozbek U, Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. *Am J Hematol.* 2004;77(3):233-40.
- Wormald S, Hilton DJ. The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways. *Curr Opin Hematol.* 2007;14(1):9-15, <http://dx.doi.org/10.1097/00062752-200701000-0-00004>.
- Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. *Blood.* 2009;113(17):4052-62, <http://dx.doi.org/10.1182/blood-2008-05-156422>.
- Reddy J, Shivapurkar N, Takahashi T, Parikh G, Stastny V, Echebiri C, et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. *Oncogene.* 2005;24(4):732-6, <http://dx.doi.org/10.1038/sj.onc.1208032>.
- Zauli G, Visani G, Bassini A, Caramelli E, Ottaviani E, Bertolaso L, et al. Nuclear translocation of protein kinase C- α and - ζ isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid (ATRA). *Br J Haematol.* 1996;93(3):542-50, <http://dx.doi.org/10.1046/j.1365-2141.1996.d01-1700.x>.
- Gibellini D, Zauli G, Re MC, Milani D, Furlini G, Caramelli E, et al. Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF- β mRNA expression and protein synthesis in peripheral blood monocytes. *Br J Haematol.* 1994;88(2):261-7, <http://dx.doi.org/10.1111/j.1365-2141.1994.tb05016.x>.
- Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. *Blood.* 2007;110(2):536-43, <http://dx.doi.org/10.1182/blood-2007-01-068395>.
- Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, et al. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. *PLoS One.* 2010;5(6):e11140, <http://dx.doi.org/10.1371/journal.pone.0011140>.
- Jaganathan BG, Tisato V, Vulliamy T, Dokal I, Marsh J, Dazzi F, Bonnet D. Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation. *Leukemia.* 2010;24(10):1791-5, <http://dx.doi.org/10.1038/leu.2010.164>.
- Zauli G, Vitale M, Gibellini D, Capitani S. Inhibition of purified CD34⁺ hematopoietic progenitor cells by human immunodeficiency virus 1 or gp120 mediated by endogenous transforming growth factor β 1. *J Exp Med.* 1996;183(1):99-108, <http://dx.doi.org/10.1084/jem.183.1.99>.
- Vitale M, Zamai L, Falcieri E, Zauli G, Gobbi P, Santi S, et al. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. *Cytometry Part B-Clin Cytometry.* 1997;30(1):61-6, [http://dx.doi.org/10.1002/\(SICI\)1097-0320\(19970215\)30:1<61::AID-CYTO9>3.0.CO;2-I](http://dx.doi.org/10.1002/(SICI)1097-0320(19970215)30:1<61::AID-CYTO9>3.0.CO;2-I).
- Campioni D, Corallini A, Zauli G, Possati L, Altavilla G, Barbanti-Brodano G. HIV type 1 extracellular tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. *AIDS Research and Human Retroviruses.* 1995;11(9):1039-48, <http://dx.doi.org/10.1089/aid.1995.11.1039>.
- Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. *Am J Pathol.* 2005;166(2):557-63.
- Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, et al. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in



- acute myeloid leukemic cells irrespectively of FLT3 and p53 status. *Haematologica*. 2012 Nov;97(11):1722-30.
28. Borgatti P, Mazzoni M, Carini C, Neri LM, Marchisio M, Bertolaso L, et al. Changes of nuclear protein kinase C activity and isotype composition in PC12 cell proliferation and differentiation. *Exp Cell Res*. 1996;224(1):72-8, <http://dx.doi.org/10.1006/excr.1996.0112>.
29. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S. Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. *J Biol Chem*. 1996;271(38):22961-4.
30. Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, et al. Nutlin-3 down-regulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic (B-CLL) cells. *Clin Cancer Res*. 2011;17(17):5649-55, <http://dx.doi.org/10.1158/1078-0432.CCR-11-1064>.
31. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells through targeting SOCS1. *Immunity*. 2009;30(1):80-91, <http://dx.doi.org/10.1016/j.immuni.2008.11.010>.
32. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. *Cancer Res*. 2010;70(8):3119-27, <http://dx.doi.org/10.1158/0008-5472.CAN-09-4250>.
33. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. *Blood*. 2008;111(10):5078-85, <http://dx.doi.org/10.1182/blood-2008-01-133355>.
34. Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. *Am J Haematol*. 2010;85(5):331-9.
35. Madonna S, Scarponi C, De Pità O, Albanesi C. Suppressor of cytokine signaling 1 inhibits IFN-gamma inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation. *FASEB J*. 2008;22(9):3287-97, <http://dx.doi.org/10.1096/fj.08-106831>.
36. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 acute leukemias cells. *Immunity*. 1999;10(1):105-15, [http://dx.doi.org/10.1016/S1074-7613\(00\)80011-4](http://dx.doi.org/10.1016/S1074-7613(00)80011-4).
37. Zauli G, Voltan R, Tisato V, Secchiero P. State of the art of the therapeutic perspective of sorafenib against hematological malignancies. *Curr Med Chem*. 2012;19(28):4875-84, <http://dx.doi.org/10.2174/092986712803341548>.
38. Tisato V, Norcio A, Voltan R, Celeghini C, Zella D, Secchiero P. MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies. *Curr Med Chem*. 2013;20(17):2226-36, <http://dx.doi.org/10.2174/0929867311320170007>.